Lumos Pharma, Inc. (LUMO)
After hours:
| Previous close | 7.99 |
| Open | 7.81 |
| Bid | 8.90 x 1300 |
| Ask | 9.20 x 1000 |
| Day's range | 7.72 - 9.09 |
| 52-week range | 6.15 - 20.34 |
| Volume | |
| Avg. volume | 38,954 |
| Market cap | 75.969M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.27 |
| Earnings date | 07 Mar 2022 - 11 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.00 |
- GlobeNewswire
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00AM ET on January 10th through the following link: https://journey.ct.events/view/d2cd046c-ff2c-40ea-acdc-340df7150783 and on Lumos Pharma’s website in
- Zacks
Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround
Lumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Simply Wall St.
We're Hopeful That Lumos Pharma (NASDAQ:LUMO) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
